These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1021 related articles for article (PubMed ID: 21719641)

  • 21. Disease mutant analysis identifies a new function of DAXX in telomerase regulation and telomere maintenance.
    Tang M; Li Y; Zhang Y; Chen Y; Huang W; Wang D; Zaug AJ; Liu D; Zhao Y; Cech TR; Ma W; Songyang Z
    J Cell Sci; 2015 Jan; 128(2):331-41. PubMed ID: 25416818
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
    Ahvenainen TV; Mäkinen NM; von Nandelstadh P; Vahteristo MEA; Pasanen AM; Bützow RC; Vahteristo PM
    Cancer; 2018 Dec; 124(24):4650-4656. PubMed ID: 30423196
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hypo-methylation mediates chromosomal instability in pancreatic NET.
    Marinoni I; Wiederkeher A; Wiedmer T; Pantasis S; Di Domenico A; Frank R; Vassella E; Schmitt A; Perren A
    Endocr Relat Cancer; 2017 Mar; 24(3):137-146. PubMed ID: 28115389
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of ATRX and DAXX in pancreatic neuroendocrine tumors: Association with recurrence risk, cellular phenotype, and heterogeneity.
    Yasunaga Y; Tanaka M; Arita J; Hasegawa K; Ushiku T
    Hum Pathol; 2024 Aug; 150():51-57. PubMed ID: 38909708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Telomere length abnormalities and telomerase RNA component expression in gastroenteropancreatic neuroendocrine tumors.
    Kim HS; Lee HS; Nam KH; Choi J; Kim WH
    Anticancer Res; 2015 Jun; 35(6):3501-10. PubMed ID: 26026117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EBV tegument protein BNRF1 disrupts DAXX-ATRX to activate viral early gene transcription.
    Tsai K; Thikmyanova N; Wojcechowskyj JA; Delecluse HJ; Lieberman PM
    PLoS Pathog; 2011 Nov; 7(11):e1002376. PubMed ID: 22102817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DAXX, ATRX, and MSI in PanNET and Their Metastases: Correlation with Histopathological Data and Prognosis.
    Gisder DM; Overheu O; Keller J; Nöpel-Dünnebacke S; Uhl W; Reinacher-Schick A; Tannapfel A; Tischoff I
    Pathobiology; 2023; 90(2):71-80. PubMed ID: 35691289
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors.
    Chou A; Itchins M; de Reuver PR; Arena J; Clarkson A; Sheen A; Sioson L; Cheung V; Perren A; Nahm C; Mittal A; Samra JS; Pajic M; Gill AJ
    Hum Pathol; 2018 Dec; 82():249-257. PubMed ID: 30081149
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ATRX represses alternative lengthening of telomeres.
    Napier CE; Huschtscha LI; Harvey A; Bower K; Noble JR; Hendrickson EA; Reddel RR
    Oncotarget; 2015 Jun; 6(18):16543-58. PubMed ID: 26001292
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Context matters - Daxx and Atrx are not robust tumor suppressors in the murine endocrine pancreas.
    Sun C; Estrella JS; Whitley EM; Chau GP; Lozano G; Wasylishen AR
    Dis Model Mech; 2022 Aug; 15(8):. PubMed ID: 35976056
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular and morphologic correlates of the alternative lengthening of telomeres phenotype in high-grade astrocytomas.
    Nguyen DN; Heaphy CM; de Wilde RF; Orr BA; Odia Y; Eberhart CG; Meeker AK; Rodriguez FJ
    Brain Pathol; 2013 May; 23(3):237-43. PubMed ID: 22928601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suppression of the alternative lengthening of telomere pathway by the chromatin remodelling factor ATRX.
    Clynes D; Jelinska C; Xella B; Ayyub H; Scott C; Mitson M; Taylor S; Higgs DR; Gibbons RJ
    Nat Commun; 2015 Jul; 6():7538. PubMed ID: 26143912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome.
    Liau JY; Tsai JH; Jeng YM; Lee JC; Hsu HH; Yang CY
    Am J Surg Pathol; 2015 Feb; 39(2):236-44. PubMed ID: 25229770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Significance of Altered ATRX/DAXX Gene in Pancreatic Neuroendocrine Tumors: A Meta-Analysis.
    Wang F; Xu X; Ye Z; Qin Y; Yu X; Ji S
    Front Endocrinol (Lausanne); 2021; 12():691557. PubMed ID: 34220718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors.
    Park JK; Paik WH; Lee K; Ryu JK; Lee SH; Kim YT
    Oncotarget; 2017 Jul; 8(30):49796-49806. PubMed ID: 28591701
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas.
    Liau JY; Tsai JH; Yang CY; Lee JC; Liang CW; Hsu HH; Jeng YM
    Hum Pathol; 2015 Sep; 46(9):1360-6. PubMed ID: 26190196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres.
    Lewis PW; Elsaesser SJ; Noh KM; Stadler SC; Allis CD
    Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14075-80. PubMed ID: 20651253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic and Predictive Biomarkers for Pancreatic Neuroendocrine Tumors.
    Hackeng WM; Assi HA; Westerbeke FHM; Brosens LAA; Heaphy CM
    Surg Pathol Clin; 2022 Sep; 15(3):541-554. PubMed ID: 36049835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.
    Schwartzentruber J; Korshunov A; Liu XY; Jones DT; Pfaff E; Jacob K; Sturm D; Fontebasso AM; Quang DA; Tönjes M; Hovestadt V; Albrecht S; Kool M; Nantel A; Konermann C; Lindroth A; Jäger N; Rausch T; Ryzhova M; Korbel JO; Hielscher T; Hauser P; Garami M; Klekner A; Bognar L; Ebinger M; Schuhmann MU; Scheurlen W; Pekrun A; Frühwald MC; Roggendorf W; Kramm C; Dürken M; Atkinson J; Lepage P; Montpetit A; Zakrzewska M; Zakrzewski K; Liberski PP; Dong Z; Siegel P; Kulozik AE; Zapatka M; Guha A; Malkin D; Felsberg J; Reifenberger G; von Deimling A; Ichimura K; Collins VP; Witt H; Milde T; Witt O; Zhang C; Castelo-Branco P; Lichter P; Faury D; Tabori U; Plass C; Majewski J; Pfister SM; Jabado N
    Nature; 2012 Jan; 482(7384):226-31. PubMed ID: 22286061
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice?
    Luchini C; Lawlor RT; Bersani S; Vicentini C; Paolino G; Mattiolo P; Pea A; Cingarlini S; Milella M; Scarpa A
    Curr Oncol Rep; 2021 Jul; 23(9):106. PubMed ID: 34269919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 52.